CR

CASSANDRA RICCI

F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES · WASHINGTON, DC · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
4
2 agencies contacted
Activity
filings by quarter
Works on

Background

Career
WASHINGTON, DC
2024 - present

Specific issues

(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Medicare/Medicaid · 2024 Q4
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Medicare/Medicaid · 2024 Q3
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Medical/Disease Research/Clinical Labs · 2024 Q3
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Medical/Disease Research/Clinical Labs · 2024 Q2
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Medicare/Medicaid · 2024 Q1
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Medical/Disease Research/Clinical Labs · 2024 Q1

Clients

$██,███ / qtrUnlock

Filing history

2024 Q4
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Q4lda.gov →
2024 Q3
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Q3lda.gov →
2024 Q2
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Q2lda.gov →
2024 Q1
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
Q1lda.gov →
Showing recent filings · full history on lda.gov